Brief: Synaptogenix Announces FDA Authorization Of IND Application For Clinical Trial For Bryostatin-1 In Multiple Sclerosis
26/06/2024 14:48
June 26 (Reuters) - Synaptogenix Inc SNPX.O :
* SYNAPTOGENIX ANNOUNCES FDA AUTHORIZATION OF IND
APPLICATION FOR
CLINICAL TRIAL FOR BRYOSTATIN-1 IN MULTIPLE SCLEROSIS
Source text for Eikon: ID:nPn8pZ1pCa
Further company coverage: SNPX.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on TAO Synergies
See all newsBrief: Tao Synergies Announces Preliminary Inclusion In Russell Microcap Index For 2026
Brief: Tao Synergies Inc - Increases Tao Holdings to 54,058 Tokens
Brief: Tao Synergies Accelerates Decentralized AI Treasury Strategy With 42,111 Bittensor Tokens
Brief: Synaptogenix Renamed TAO Synergies, New Ticker "TAOX" for AI-Focused Crypto Strategy
Brief: Synaptogenix Announces Initial TAO Acquisition Under Crypto Treasury Strategy